R Squared’s Myriad Genetics MYGN Stock Holding History

R Squared’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-134	Closed	-$1.84K	–	1044
2024 Q4	$1.84K	Buy	+134	New	+$2.47K	﹤0.01%	1470

Other funds holding MYGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

DGI

Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

GCM

Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

R Squared's MYGN Position: Q1 2025 in Review

R Squared sold out of Myriad Genetics (MYGN) in Q1 2025, closing a stake of 134 shares — an estimated $1.84K sold.

R Squared first reported a position in MYGN in Q4 2024 and held it in 1 quarter. The position peaked at $1.84K in Q4 2024. 228 funds tracked by Wall St. Rank hold MYGN as of Q1 2025.

R Squared reported no remaining Myriad Genetics position as of Q1 2025 after selling out during the quarter.
R Squared sold 134 Myriad Genetics shares in Q1 2025, an estimated $1.84K.
R Squared first reported a position in Myriad Genetics in Q4 2024 and held it in 1 quarter.
R Squared's Myriad Genetics position peaked at $1.84K in Q4 2024.
228 funds tracked by Wall St. Rank held Myriad Genetics as of Q1 2025.

Based on R Squared's 13F filing for Q1 2025, filed 9 May 2025.